From Cells to Targeted Therapy: Cytopathology as the Starting Point of Precision Oncology in the Molecular Tumor Board Workflow
Acta Cytologica · 08.05.2026 · 1-9
DOI: 10.1159/000552314 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Cytologica, online erschienen am 08.05.2026. Verfasst von Ricella Souza da Silva und 1 weiteren Autor:innen. Beteiligte Einrichtung: IPATIMUP Diagnostics, IPATIMUP - Institute of Molecular Pathology and Immunology of Porto University, Porto, Portugal. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background: Precision oncology is often portrayed as a story of genes and drugs, yet it begins with a cell on a slide. This review positions cytopathology as the front door to Molecular Tumor Boards (MTBs), showing how minimally invasive specimens can reliably power comprehensive genomic profiling and guide targeted therapy decisions. Summary: We summarize current evidence and international recommendations to outline a practical, cytology-centered MTB workflow, from case selection and sample triage to technical and clinical validation of molecular alterations, structured reporting, and outcome monitoring. Particular emphasis is placed on pre-analytic variables, nucleic acid yield, and cytomorphologic assessment as determinants of next-generation sequencing success, as well as on the use of cytology-derived preparations, such as cell blocks, smears, body fluids, and supernatants, as site-specific “liquid biopsies” in advanced and difficult to biopsy tumors. We also revise some operational bottlenecks and discuss how integrative pathology can enhance MTB efficiency and equity. Key Messages: Cytopathology is the front door to MTBs, enabling minimally invasive specimens to power comprehensive genomic profiling and guide targeted therapy decisions. Pre-analytic variables, nucleic acid yield, and cytomorphologic assessment is determinants of next-generation sequencing success. A practical, cytology-centered MTB workflow from case selection and sample triage to technical and clinical validation of molecular alterations, structured reporting, and outcome monitoring. By reframing cytology from a fallback option to a strategic starting point, this article proposes a model in which cytopathologists co-drive MTB deliberations, enabling timely, evidence-based, and patient-centered precision oncology from the least invasive samples available.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IPATIMUP Diagnostics, IPATIMUP - Institute of Molecular Pathology and Immunology of Porto University, Porto, Portugal.
- RISE-Health, Department of Pathology, Faculty of Medicine of the University of Porto, Porto, Portugal.
- IPATIMUP Diagnostics, IPATIMUP - Institute of Molecular Pathology and Immunology of Porto University, Porto, Portugal, fschmitt@ipatimup.pt.
- RISE-Health, Department of Pathology, Faculty of Medicine of the University of Porto, Porto, Portugal, fschmitt@ipatimup.pt.
Zitieren
APA
Souza da Silva, R., & Schmitt, F. C. (2026). From Cells to Targeted Therapy: Cytopathology as the Starting Point of Precision Oncology in the Molecular Tumor Board Workflow. Acta Cytologica, 1-9. https://doi.org/10.1159/000552314
Vancouver
Souza da Silva R, Schmitt FC. From Cells to Targeted Therapy: Cytopathology as the Starting Point of Precision Oncology in the Molecular Tumor Board Workflow. Acta Cytologica. 2026:1-9. doi:10.1159/000552314
BibTeX
@article{SouzadaSilva2026,
author = {Souza da Silva, Ricella and Schmitt, Fernando C},
title = {From Cells to Targeted Therapy: Cytopathology as the Starting Point of Precision Oncology in the Molecular Tumor Board Workflow},
journal = {Acta Cytologica},
year = {2026},
pages = {1--9},
doi = {10.1159/000552314}
}
EUVIMED